Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
2.380
-0.060 (-2.46%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Quantum BioPharma Employees
Quantum BioPharma had 17 employees as of December 31, 2022. The number of employees increased by 7 or 70.00% compared to the previous year. That makes Quantum BioPharma the 38,949th largest employer in the world and 5,658th in the United States.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,479,927
Market Cap
20.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2022 | 17 | 7 | 70.00% | 17 | 0 |
| Dec 31, 2021 | 10 | 1 | 11.11% | 10 | 0 |
| Dec 31, 2020 | 9 | -9 | -50.00% | 9 | 0 |
| Dec 31, 2019 | 18 | -1 | -5.26% | 17 | 1 |
| Sep 30, 2019 | 23 | 4 | 21.05% | 23 | 0 |
| Jun 30, 2019 | 19 | - | - | 19 | 0 |
| Dec 31, 2018 | 19 | - | - | 19 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Seres Therapeutics | 66 |
| Kyntra Bio | 34 |
| Jasper Therapeutics | 22 |
| Atossa Therapeutics | 16 |
| Context Therapeutics | 15 |
| Actuate Therapeutics | 12 |
| Cocrystal Pharma | 10 |
QNTM News
- 3 days ago - 3 Quantum Computing ETFs with 30%+ Upside Potential, According to Analysts - TipRanks
- 25 days ago - Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial - TheFly
- 25 days ago - Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewsWire
- 4 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma licensee Unbuzzed Wellness appoints Zapolin as CEO - TheFly
- 5 weeks ago - Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO - GlobeNewsWire
- 6 weeks ago - Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target - GlobeNewsWire
- 6 weeks ago - Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto - Newsfile Corp